Skip to content

US · LGND · BIOTECHNOLOGY

Ligand Pharmaceuticals Incorporated (LGND) intrinsic value and stock valuation

$286.85as of 2026-11-21 · Mkt cap 5.88B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Ligand Pharmaceuticals Incorporated DCF and intrinsic value

InvestorsCraft values LGND with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from LGND’s statements →

Ligand Pharmaceuticals Incorporated Graham Number

Graham Number: $87.27d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Jupiter, FL 33458 ligand.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$268.1M+10.4% 5y CAGRd
20112025
Net income
$124.5M
20112025
Free cash flow
$48.9M-0.5% 5y CAGRd
20112025
Total equity
$1.02B+7.5% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$268.1M$167.1M$131.3M$196.3M$241.5M
Operating income$47.2M-$-22.61M$11.9M$3.04M$103.9M
Net income$124.5M-$-4.03M$52.2M-$-33.36M$57.1M
EPSd$6.13M-$-220.34K$2.94M-$-1.98M$3.31M
Operating cash flow$49.4M$97.1M$49.6M$137.9M$78.8M
Capital expenditure-$-450K-$-19.64M-$-53.85M-$-17.92M-$-8.76M
Free cash flow$48.9M$77.4M-$-4.27M$119.9M$70M
Total assets$1.56B$941.8M$787.2M$762.7M$1.3B
Total debt$451.5M$7.11M$6.17M$87.8M$324.4M
Net debt$276.6M-$-65.2M-$-16.79M$42.7M$304.9M
Total equity$1.02B$830.4M$700.9M$597.5M$821.2M
Cash and short-term investments$733.5M$256.2M$170.3M$211.9M$341.1M
Income statement
20252024202320222021
Revenue$268.1M$167.1M$131.3M$196.3M$241.5M
Cost of revenue$6.59M$11.1M$35.1M$52.8M$62.2M
Gross profit$261.5M$156.1M$96.3M$143.4M$179.4M
Research and development expenses$81.2M$21.4M$24.5M$36.1M$32.1M
Selling, general and administrative expenses$92.5M$78.7M$52.8M$70.1M$46.8M
Other expenses$40.7M$78.6M$7M$34.2M-$-3.38M
Operating expenses$214.3M$178.7M$84.3M$140.4M$75.5M
Cost and expenses$220.9M$189.7M$119.4M$193.2M$137.7M
Interest income$13.7M$8.05M$7.71M$2.05M$890K
Interest expense$4.71M$3.04M$660K$1.8M$19.6M
Depreciation and amortization$33.8M$35.2M$36.5M$43.4M$51M
Ebitda$192.7M$40.8M$100.8M$81.2M$142.8M
Operating income$47.2M-$-22.61M$11.9M$3.04M$103.9M
Total other income/expenses, net$111.8M$25.1M$51.7M$33M-$-31.65M
Income before tax$159M$2.52M$63.7M$36M$72.2M
Income tax expense$34.5M$6.55M$9.84M$41.2M-$-4.15M
Net income$124.5M-$-4.03M$52.2M-$-33.36M$57.1M
Weighted average shares outstanding$19.3M$18.3M$17.3M$16.9M$16.6M
Weighted average diluted shares outstanding$20.3M$18.3M$17.8M$16.9M$17.3M
Balance sheet
20252024202320222021
Cash and short-term investments$733.5M$256.2M$170.3M$211.9M$341.1M
Net receivables$61.1M$42.5M$39.3M$35M$91.7M
Inventory$9.13M$14.1M$24M$13.3M$27.3M
Total current assets$832.3M$331.6M$237.4M$263.6M$464.8M
Property, plant and equipment, net$10.8M$24.8M$25.1M$27.5M$32.6M
Goodwill and intangible assets$523.9M$371.9M$403M$458.3M$492.5M
Long-term investments$183.6M$10.9M$111.6M$3M$0.00
Total non-current assets$728.4M$610.2M$549.8M$499.1M$832.8M
Total assets$1.56B$941.8M$787.2M$762.7M$1.3B
Accounts payable$3.24M$5.23M$2.43M$5.31M$8.4M
Short-term debt$1.09M$1.29M$410K$77.4M$1.41M
Deferred revenue$620K$1.9M$1.84M$980K$650K
Total current liabilities$37.5M$37.1M$16.8M$98.8M$41.7M
Long-term debt$450.4M$5.82M$5.75M$10.3M$323M
Deferred revenue, non-current$0.00$0.00$15.1M$40K$0.00
Total non-current liabilities$506M$74.2M$69.5M$66.4M$434.8M
Capital lease obligations$5.3M$7.11M$6.17M$11.1M$3.67M
Total liabilities$543.4M$111.3M$86.3M$165.2M$476.4M
Common stock$20K$20K$20K$20K$20K
Retained earnings$608.1M$499M$503M$450.9M$449.1M
Accumulated other comprehensive income (loss)$8.46M-$-5.94M-$-820K-$-980K-$-920K
Total equity$1.02B$830.4M$700.9M$597.5M$821.2M
Total investments$742.2M$194.8M$259M$169.9M$321.6M
Total debt$451.5M$7.11M$6.17M$87.8M$324.4M
Net debt$276.6M-$-65.2M-$-16.79M$42.7M$304.9M
Cash flow statement
20252024202320222021
Net income$124.5M-$-4.03M$52.2M-$-33.36M$57.1M
Depreciation and amortization$35.7M$35.2M$36.5M$51.4M$51M
Stock-based compensation$0.00$41.1M$25.7M$60.3M$38.8M
Change in working capital-$-12.66M$19.4M-$-34.4M$65.7M-$-52.16M
Accounts receivable-$-21.74M-$-6.46M-$-2.6M$55.3M-$-28.62M
Inventory$4.99M$9.62M-$-10.87M$12.1M-$-430K
Accounts payable$5.88M$0.00-$-4.7M-$-3.34M-$-1.17M
Net cash provided by operating activities$49.4M$97.1M$49.6M$137.9M$78.8M
Investments in property, plant and equipment-$-11.31M-$-1.82M-$-3.52M-$-17.92M-$-8.76M
Acquisitions, net-$-8.09M-$-172.19M-$-25.65M-$-750K$490K
Net cash used for investing activities-$-377.32M-$-143.66M-$-11.68M$163.6M$30.5M
Common stock issued$114.9M$37.1M$22.5M$3.23M$33.8M
Common stock repurchased-$-15M$0.00$0.00$0.00-$-18.45M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$428.2M$97.1M-$-59.95M-$-275.99M-$-137.76M
Net change in cash$102.6M$49.4M-$-22.05M$25.5M-$-28.44M
Cash at end of period$174.9M$72.3M$23M$45M$19.5M
Operating cash flow$49.4M$97.1M$49.6M$137.9M$78.8M
Capital expenditure-$-450K-$-19.64M-$-53.85M-$-17.92M-$-8.76M
Free cash flow$48.9M$77.4M-$-4.27M$119.9M$70M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Ligand Pharmaceuticals Incorporated

        Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.

        CEO
        Todd C. Davis
        Employees
        47
        Beta
        1.07

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Ligand Pharmaceuticals Incorporated (LGND)?

        Ligand Pharmaceuticals Incorporated (LGND) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is LGND undervalued?

        LGND trades at a price of $286.85 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.